Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference being held from February 5-6, 2025 in New York.
Details of the event are as follows: Date: Wednesday, February 5, 2025 Time: 2:00 p.m. ET
The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129760119/en/
Adicet Bio, Inc. Investor and Media Contacts
Investors: Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Precision AQ 212-362-1200 janhavi.mohite@precisionaq.com
Media: Kerry Beth Daly kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Advanced%20Charting%20%7C%20Nasdaq&_biz_n=0&rnd=468660&cdn_o=a&_biz_z=1741683130381)
